David Meyronet

Summary

Affiliation: Hospices Civils de Lyon
Country: France

Publications

  1. ncbi Extensive expression of collapsin response mediator protein 5 (CRMP5) is a specific marker of high-grade lung neuroendocrine carcinoma
    David Meyronet
    INSERM, U842, Lyon, F 69372, France
    Am J Surg Pathol 32:1699-708. 2008
  2. ncbi Focal myositis associated with S-1 radiculopathy: report of two cases
    Nathalie Streichenberger
    Service de Neuropathologie, Hopital Neurologique, BP Lyon Montchat, 69394 Lyon, France
    Muscle Nerve 29:443-6. 2004
  3. ncbi [Thymic neuroendocrine tumors: report on 6 cases]
    Lara Chalabreysse
    Service d Anatomie et de Cytologie Pathologiques, Hopital Louis Pradel, 28 avenue du Doyen Lepine, 69677 Bron Cedex
    Ann Pathol 25:205-10. 2005
  4. ncbi Identification of a new CRMP5 isoform present in the nucleus of cancer cells and enhancing their proliferation
    Sébastien Brot
    INSERM, UMR S1028, CNRS, UMR 5292, Lyon Neuroscience Research Center, Neuro oncology and Neuro inflammation Team, 7, Rue Guillaume Paradin, Lyon Cedex 08 F 69372, France
    Exp Cell Res 319:588-99. 2013
  5. ncbi Selective suppression of in vivo tumorigenicity by semaphorin SEMA3F in lung cancer cells
    Sophie Kusy
    IPBC, CNRS UMR 6187, Faculté des Sciences de Poitiers, 40 Avenue du Recteur Pineau, Poitiers 86022, France
    Neoplasia 7:457-65. 2005
  6. ncbi [A pseudo aneurysmal subcutaneous tumor]
    Anne Gentil Perret
    Service d'Anatomie et de Cytologie Pathologiques, CHU, 42055 de Saint-Etienne
    Ann Pathol 23:73-5. 2003

Collaborators

  • L Chalabreysse
  • N Streichenberger
  • J Honnorat
  • Daniel Chan
  • Sébastien Brot
  • Sophie Kusy
  • Anne Gentil Perret
  • Céline Malleval
  • Claire Benetollo
  • Carole Auger
  • Veronique Rogemond
  • Mahnaz Moradi-Améli
  • Bruno Constantin
  • Vincent Potiron
  • Patrick Nasarre
  • Harry A Drabkin
  • Joëlle Roche
  • Robert M Gemmill
  • Claire Berger
  • Yves Chavrier

Detail Information

Publications6

  1. ncbi Extensive expression of collapsin response mediator protein 5 (CRMP5) is a specific marker of high-grade lung neuroendocrine carcinoma
    David Meyronet
    INSERM, U842, Lyon, F 69372, France
    Am J Surg Pathol 32:1699-708. 2008
    ..Our findings point at CRMP5 as a novel marker for routine pathologic evaluation of lung tumors surgical samples in distinguishing between highly aggressive neuroendocrine carcinoma and the other lung cancers...
  2. ncbi Focal myositis associated with S-1 radiculopathy: report of two cases
    Nathalie Streichenberger
    Service de Neuropathologie, Hopital Neurologique, BP Lyon Montchat, 69394 Lyon, France
    Muscle Nerve 29:443-6. 2004
    ..Muscle biopsy revealed a focal myositis associated with some features of denervation. A brief course of corticosteroids was followed by remission clinically and improvement in the MRI findings...
  3. ncbi [Thymic neuroendocrine tumors: report on 6 cases]
    Lara Chalabreysse
    Service d Anatomie et de Cytologie Pathologiques, Hopital Louis Pradel, 28 avenue du Doyen Lepine, 69677 Bron Cedex
    Ann Pathol 25:205-10. 2005
    ..the aim of our study was to analyze a series of 6 thymic neuroendocrine tumors (TNET)...
  4. ncbi Identification of a new CRMP5 isoform present in the nucleus of cancer cells and enhancing their proliferation
    Sébastien Brot
    INSERM, UMR S1028, CNRS, UMR 5292, Lyon Neuroscience Research Center, Neuro oncology and Neuro inflammation Team, 7, Rue Guillaume Paradin, Lyon Cedex 08 F 69372, France
    Exp Cell Res 319:588-99. 2013
    ..Moreover, we show that the function associated with the CRMP5 nuclear targeting is an increase of cell proliferation activity...
  5. ncbi Selective suppression of in vivo tumorigenicity by semaphorin SEMA3F in lung cancer cells
    Sophie Kusy
    IPBC, CNRS UMR 6187, Faculté des Sciences de Poitiers, 40 Avenue du Recteur Pineau, Poitiers 86022, France
    Neoplasia 7:457-65. 2005
    ..Thus, in this in vivo lung cancer model, SEMA3F has potent antitumor effects, which may impinge on activated integrin and MAPK signaling...
  6. ncbi [A pseudo aneurysmal subcutaneous tumor]
    Anne Gentil Perret
    Service d'Anatomie et de Cytologie Pathologiques, CHU, 42055 de Saint-Etienne
    Ann Pathol 23:73-5. 2003